Predictive impact of MGMT promoter methylation in glioblastoma of the elderly

摘要: O(6)-methylguanine-DNA-methyltransferase (MGMT) promoter methylation identifies a subpopulation of glioblastoma patients with more favorable prognosis and predicts benefit from alkylating agent chemotherapy (CT). Little is known about its prevalence clinical significance in older patients. We studied 233 aged 70 years or (144 males, 89 females, median age: 74 years, range: 70.0-86.6 years), who were prospectively enrolled the German Glioma Network, for MGMT by methylation-specific PCR (MSP) all DNA pyrosequencing 166 data correlated patient outcome. Median progression-free survival (PFS) was 4.8 months (95% CI: 4.3-5.3) overall (OS) 7.7 6.3-9.0). detected MSP 134 (57.5%). For whole cohort, PFS 5.2 versus 4.7 (p = 0.207) OS 8.4 6.4 0.031) without methylation. Patients methylated tumors had longer when treated radiotherapy (RT) plus CT alone compared to RT alone. unmethylated appeared derive no CT, regardless whether given at diagnosis together as salvage treatment. demonstrated revealed >25% alleles. Taken together, may be useful biomarker stratify elderly treatment CT.